Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
GRTS - Gritstone Oncology Inc
0.28(2.58%)6:00:00 PM 11/26/2021
Gritstone Oncology, Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate which is in Phase I/2 clinical study for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.


  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
Stock Statistics
PE Ratio
PEG Ratio
P/S (ttm)11.4
Earning Growth (QoQ)
Revenue Growth (QoQ)
Short %12%
Held by Institutions %71%
1 Day Vol Adjusted Return0.8
1 Month Vol Adjusted Return1.0
3 Month Vol Adjusted Return5.2
6 Month Vol Adjusted Return4.5
20 Days SMA Price ZScore0.2
50 Days SMA Price ZScore0.7
12 -26 Days PPO1.2
1 Month Average Short Volume Ratio29.3
1 Day Volume Change ZScore-1.0
1 Month Daily Vol3.4
Related Topics
leak data

Related Topics


Related Peers

Stock news